Which has better valuation & earnings, PROK or EQ?

Equillium has higher revenue and earnings than ProKidney. Equillium is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ProKidney $890K 652.20 -$68.99M -$0.55 N/A Equillium $41.10M 3.43 -$22.40M -$0.20 N/A

Is PROK or EQ more profitable?

Equillium has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets ProKidney -10,288.39% N/A -27.39% Equillium N/A -41.15% -38.29%

Is EQ or EIKN more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -41.15% -38.29% Eikon Therapeutics N/A N/A N/A

Does the media favor EQ or EIKN?

In the previous week, Eikon Therapeutics had 4 more articles in the media than Equillium. MarketBeat recorded 6 mentions for Eikon Therapeutics and 2 mentions for Equillium. Eikon Therapeutics' average media sentiment score of 0.91 beat Equillium's score of 0.90 indicating that Eikon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eikon Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EQ or ARTV more profitable?

Equillium's return on equity of -41.15% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -41.15% -38.29% Artiva Biotherapeutics N/A -53.86% -48.16%

Does the media prefer EQ or ARTV?

In the previous week, Artiva Biotherapeutics had 5 more articles in the media than Equillium. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 2 mentions for Equillium. Equillium's average media sentiment score of 0.90 beat Artiva Biotherapeutics' score of 0.70 indicating that Equillium is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Artiva Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, EQ or ZURA?

Equillium has higher revenue and earnings than Zura Bio. Equillium is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Equillium $41.10M 3.43 -$22.40M -$0.20 N/A Zura Bio N/A N/A -$99.35M -$1.13 N/A

Is EQ or ZURA more profitable?

Equillium's return on equity of -41.15% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -41.15% -38.29% Zura Bio N/A -56.13% -50.15%

Does the media refer more to EQ or ZURA?

In the previous week, Equillium had 1 more articles in the media than Zura Bio. MarketBeat recorded 2 mentions for Equillium and 1 mentions for Zura Bio. Equillium's average media sentiment score of 0.90 beat Zura Bio's score of 0.80 indicating that Equillium is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zura Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EQ or CABA more profitable?

Equillium's return on equity of -41.15% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -41.15% -38.29% Cabaletta Bio N/A -128.27% -95.47%

Does the media favor EQ or CABA?

In the previous week, Cabaletta Bio had 4 more articles in the media than Equillium. MarketBeat recorded 6 mentions for Cabaletta Bio and 2 mentions for Equillium. Equillium's average media sentiment score of 0.90 beat Cabaletta Bio's score of 0.57 indicating that Equillium is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cabaletta Bio 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Equillium (EQ) Competitors

$2.22 -0.03 (-1.33%)

As of 09/3/2026 04:00 PM Eastern

Compare

EQ vs. PROK, EIKN, ARTV, ZURA, and CABA

Should you buy Equillium stock or one of its competitors? Equillium's main competitors and comparable companies include ProKidney (PROK), Eikon Therapeutics (EIKN), Artiva Biotherapeutics (ARTV), Zura Bio (ZURA), and Cabaletta Bio (CABA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Equillium compare to ProKidney?

ProKidney (NASDAQ:PROK) and Equillium (NASDAQ:EQ) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Equillium has higher revenue and earnings than ProKidney. Equillium is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	652.20	-$68.99M	-$0.55	N/A
Equillium	$41.10M	3.43	-$22.40M	-$0.20	N/A

ProKidney has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market. Comparatively, Equillium has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

In the previous week, Equillium had 2 more articles in the media than ProKidney. MarketBeat recorded 2 mentions for Equillium and 0 mentions for ProKidney. Equillium's average media sentiment score of 0.90 beat ProKidney's score of 0.00 indicating that Equillium is being referred to more favorably in the news media.

Company	Overall Sentiment
ProKidney	Neutral
Equillium	Positive

Equillium has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-10,288.39%	N/A	-27.39%
Equillium	N/A	-41.15%	-38.29%

ProKidney presently has a consensus target price of $12.00, indicating a potential upside of 525.00%. Equillium has a consensus target price of $7.57, indicating a potential upside of 241.06%. Given ProKidney's higher possible upside, research analysts clearly believe ProKidney is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

51.6% of ProKidney shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 17.8% of Equillium shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Equillium beats ProKidney on 10 of the 17 factors compared between the two stocks.

How does Equillium compare to Eikon Therapeutics?

Equillium (NASDAQ:EQ) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

Equillium has higher revenue and earnings than Eikon Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	3.43	-$22.40M	-$0.20	N/A
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A

27.1% of Equillium shares are owned by institutional investors. 17.8% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Equillium currently has a consensus target price of $7.57, indicating a potential upside of 241.06%. Eikon Therapeutics has a consensus target price of $25.00, indicating a potential upside of 128.10%. Given Equillium's stronger consensus rating and higher possible upside, research analysts plainly believe Equillium is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, Eikon Therapeutics had 4 more articles in the media than Equillium. MarketBeat recorded 6 mentions for Eikon Therapeutics and 2 mentions for Equillium. Eikon Therapeutics' average media sentiment score of 0.91 beat Equillium's score of 0.90 indicating that Eikon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eikon Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eikon Therapeutics' return on equity of 0.00% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-41.15%	-38.29%
Eikon Therapeutics	N/A	N/A	N/A

Summary

Equillium beats Eikon Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Equillium compare to Artiva Biotherapeutics?

Equillium (NASDAQ:EQ) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Equillium has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.18, suggesting that its stock price is 118% more volatile than the broader market.

In the previous week, Artiva Biotherapeutics had 5 more articles in the media than Equillium. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 2 mentions for Equillium. Equillium's average media sentiment score of 0.90 beat Artiva Biotherapeutics' score of 0.70 indicating that Equillium is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Artiva Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Equillium has higher revenue and earnings than Artiva Biotherapeutics. Equillium is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	3.43	-$22.40M	-$0.20	N/A
Artiva Biotherapeutics	$250K	2,176.58	-$83.86M	-$3.30	N/A

Equillium's return on equity of -41.15% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-41.15%	-38.29%
Artiva Biotherapeutics	N/A	-53.86%	-48.16%

Equillium presently has a consensus target price of $7.57, suggesting a potential upside of 241.06%. Artiva Biotherapeutics has a consensus target price of $39.00, suggesting a potential upside of 250.40%. Given Artiva Biotherapeutics' higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

27.1% of Equillium shares are held by institutional investors. 17.8% of Equillium shares are held by company insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Equillium beats Artiva Biotherapeutics on 11 of the 16 factors compared between the two stocks.

How does Equillium compare to Zura Bio?

Equillium (NASDAQ:EQ) and Zura Bio (NASDAQ:ZURA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

In the previous week, Equillium had 1 more articles in the media than Zura Bio. MarketBeat recorded 2 mentions for Equillium and 1 mentions for Zura Bio. Equillium's average media sentiment score of 0.90 beat Zura Bio's score of 0.80 indicating that Equillium is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zura Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Equillium presently has a consensus price target of $7.57, suggesting a potential upside of 241.06%. Zura Bio has a consensus price target of $17.00, suggesting a potential upside of 189.12%. Given Equillium's stronger consensus rating and higher possible upside, research analysts plainly believe Equillium is more favorable than Zura Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Equillium's return on equity of -41.15% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-41.15%	-38.29%
Zura Bio	N/A	-56.13%	-50.15%

27.1% of Equillium shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 17.8% of Equillium shares are owned by insiders. Comparatively, 12.4% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Equillium has higher revenue and earnings than Zura Bio. Equillium is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	3.43	-$22.40M	-$0.20	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A

Equillium has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market. Comparatively, Zura Bio has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market.

Summary

Equillium beats Zura Bio on 13 of the 15 factors compared between the two stocks.

How does Equillium compare to Cabaletta Bio?

Equillium (NASDAQ:EQ) and Cabaletta Bio (NASDAQ:CABA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

In the previous week, Cabaletta Bio had 4 more articles in the media than Equillium. MarketBeat recorded 6 mentions for Cabaletta Bio and 2 mentions for Equillium. Equillium's average media sentiment score of 0.90 beat Cabaletta Bio's score of 0.57 indicating that Equillium is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cabaletta Bio	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Equillium has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.27, suggesting that its share price is 227% more volatile than the broader market.

Equillium's return on equity of -41.15% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-41.15%	-38.29%
Cabaletta Bio	N/A	-128.27%	-95.47%

Equillium presently has a consensus target price of $7.57, suggesting a potential upside of 241.06%. Cabaletta Bio has a consensus target price of $15.33, suggesting a potential upside of 340.61%. Given Cabaletta Bio's higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Equillium has higher revenue and earnings than Cabaletta Bio. Equillium is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	3.43	-$22.40M	-$0.20	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A

27.1% of Equillium shares are owned by institutional investors. 17.8% of Equillium shares are owned by company insiders. Comparatively, 6.4% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Equillium beats Cabaletta Bio on 11 of the 15 factors compared between the two stocks.

Get Equillium News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EQ vs. The Competition

Export

Metric	Equillium	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$142.67M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-11.10	12.66	273.29	25.38
Price / Sales	3.43	1,309.08	613.45	97.56
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	2.52	16.29	12.89	6.14
Net Income	-$22.40M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-7.11%	0.34%	0.60%	-0.27%
1 Month Performance	-1.77%	8.52%	5.73%	0.68%
1 Year Performance	26.86%	52.66%	25.35%	14.84%

Equillium Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EQ Equillium	2.3643 of 5 stars	$2.22 -1.3%	$7.57 +241.1%	+18.7%	$142.67M	$41.10M	N/A	40
PROK ProKidney	1.4016 of 5 stars	$1.85 -2.1%	$12.00 +548.6%	-18.6%	$571.39M	$890K	N/A	3
EIKN Eikon Therapeutics	3.6755 of 5 stars	$10.88 +4.0%	$25.00 +129.8%	N/A	$566.57M	N/A	N/A	384	News Coverage Positive News
ARTV Artiva Biotherapeutics	2.8917 of 5 stars	$11.28 -0.2%	$39.00 +245.7%	+250.0%	$552.46M	$250K	N/A	81	Positive News Gap Down
ZURA Zura Bio	2.5325 of 5 stars	$5.65 +2.0%	$17.00 +200.9%	+189.7%	$530.89M	N/A	N/A	3	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EQ) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Equillium (EQ) Competitors

EQ vs. PROK, EIKN, ARTV, ZURA, and CABA

How does Equillium compare to ProKidney?

Summary

How does Equillium compare to Eikon Therapeutics?

Summary

How does Equillium compare to Artiva Biotherapeutics?

Summary

How does Equillium compare to Zura Bio?

Summary

How does Equillium compare to Cabaletta Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EQ vs. The Competition

Equillium Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Equillium (EQ) Competitors

EQ vs. PROK, EIKN, ARTV, ZURA, and CABA

How does Equillium compare to ProKidney?

Which has better valuation & earnings, PROK or EQ?

Which has more risk and volatility, PROK or EQ?

Does the media favor PROK or EQ?

Is PROK or EQ more profitable?

Do analysts recommend PROK or EQ?

Do institutionals & insiders believe in PROK or EQ?

Summary

How does Equillium compare to Eikon Therapeutics?

Which has higher earnings & valuation, EQ or EIKN?

Do institutionals and insiders believe in EQ or EIKN?

Do analysts rate EQ or EIKN?

Does the media favor EQ or EIKN?

Is EQ or EIKN more profitable?

Summary

How does Equillium compare to Artiva Biotherapeutics?

Which has more risk & volatility, EQ or ARTV?

Does the media prefer EQ or ARTV?

Which has higher earnings and valuation, EQ or ARTV?

Is EQ or ARTV more profitable?

Do analysts rate EQ or ARTV?

Do insiders & institutionals hold more shares of EQ or ARTV?

Summary

How does Equillium compare to Zura Bio?

Does the media refer more to EQ or ZURA?

Do analysts prefer EQ or ZURA?

Is EQ or ZURA more profitable?

Do insiders and institutionals hold more shares of EQ or ZURA?

Which has higher earnings & valuation, EQ or ZURA?

Which has more risk & volatility, EQ or ZURA?

Summary

How does Equillium compare to Cabaletta Bio?

Does the media favor EQ or CABA?

Which has more volatility & risk, EQ or CABA?

Is EQ or CABA more profitable?

Do analysts recommend EQ or CABA?

Which has higher earnings & valuation, EQ or CABA?

Do insiders and institutionals have more ownership in EQ or CABA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EQ vs. The Competition

Equillium Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools